Two recurrent mutations (-124 G > A and 2146 G > A) in the core promoter region of the human telomerase reverse transcriptase (TERT) gene create consensus binding sites for ETS transcription factors and cause increased TERT expression in several tumour types. We analyzed TERT promoter mutations and TERT mRNA levels in head and neck cancer, cervical carcinoma and cervical intraepithelial neoplasia (CIN) as well as in C-4I, CaSki, HeLa and SiHa cervical cell lines. Nucleotide sequence analysis of TERT promoter region showed that 33.3% of oral squamous cell carcinoma (SCC) and 16.8% of cervical SCC harboured mutually exclusive G to A transitions at nucleotide position 2124 or 2146. TERT promoter was mutated at nucleotide 2146 (G > A) in SiHa cell line. Other nucleotide changes creating in some cases putative ETS binding sites were more frequent in oral SCC (26.7%) than in cervical carcinoma (4.8%). The frequency of mutations was independent of human papillomavirus (HPV) tumour status in both cervical and oral cancer. Expression of TERT gene was significantly higher in TERT promoter mutated (-124G > A or 2146G > A) cervical SCC compared to not mutated SCC irrespective of HPV16 E6 and E7 levels. Such hot spot changes were not detected in oropharyngeal SCC, cervical adenocarcinoma and CIN lesions. Our results suggest that TERT promoter mutations play a relevant role in oral SCC as well as in cervical SCC, besides the already known effect of HPV16 E6 protein on TERT expression.
Introduction
Approximately 686,000 new cases of head and neck cancer and 528,000 cases of cervical carcinoma are diagnosed each year in the world. 1 The squamous cell carcinoma (SCC) of the lip, oral cavity, larynx and hypopharynx, mainly caused by tobacco and alcohol consumption, are the most frequent head and neck tumours accounting for 457,250 cases annually, despite the expected decrease due to public health campaigns. 2, 3 In parallel, the oropharyngeal cancers, comprising 96,000 cases in 2012, have shown an increasing incidence for the rising number of human papillomavirus (HPV)-related cases especially in young men in several Western countries. 3 The incidence of cervical SCC, the predominant histotype of cervical cancer, has declined steadily during last decades in many high income countries due to the success of organized oncologic screening programs but remained high in most low and medium income countries, while the rate of cervical adenocarcinoma (AC) remained unchanged in low and high income countries. 4, 5 High risk HPVs have been recognized as the necessary cause of approximately 31% of oropharyngeal SCC and above 95% of cervical SCC and AC. [6] [7] [8] The HPV-related head and neck cancers show distinct clinical and biological features. 9, 10 In particular, tumours associated with HPV have a low number of gene mutations compared to those associated with smoke and alcohol intake which harbour large numbers of genetic alterations dominantly in TP53 and CDKN2A tumour suppressor genes. 11, 12 Patients with HPV-positive head and neck tumours have a better prognosis with 5-year survival rates of approximately 75-80% compared to the 45-50% of subjects with HPV-negative tumours. 13 The HPV genotype 16 is the dominant virus in oropharyngeal SCC as well as cervical SCC accounting for 82-87% and 65-70% of all HPV-positive cases, respectively. 14, 15 The transforming mechanism of HPV16 mainly relies on the synergistic oncogenic activity of E6 and E7 viral proteins which are able to inhibit p53 and pRb oncosuppressors, respectively. 7 Moreover, these two oncoproteins interact with several other cell factors and cause activation of transforming pathways, proliferative signalling, evasion from growth suppressors, genome instability and genetic alterations. 16 Additionally, the HPV16 E6 has shown to de-repress the telomerase reverse transcriptase (TERT) promoter and to re-activate TERT gene expression in epithelial cells through its interaction with MYC and NFX-1 thus contributing to cell immortalization. 17, 18 The telomerase is a ribonucleoprotein which de novo synthesizes repeats of DNA sequences at the ends of chromosomes and regulates the genome stability and cell duplication. 19 Extinguished telomerase activity in most normal cells causes telomeres shortening, cell growth arrest and senescence while TERT reactivation is considered one of the hallmarks of cancer in the majority of tumour types. 20 Multiple mechanisms contribute to the sustained telomerase expression in cancer cells including gene mutations, chromosomal re-arrangements and altered methylation pattern of TERT promoter. 21 Two mutually exclusive G-A mutations at nucleotide 2124 and 2146 within the core promoter region of TERT gene have shown to occur in over 50 tumour types. 22, 23 Both hot spot mutations generate two identical nucleotide sequences (5 0 -CCCCTTCCGGG-3 0 ) containing consensus binding sites for E-twenty-six (ETS) transcription factors. 24 The activation of ETS family genes has been observed in most solid tumours in all stages of tumorigenesis thus the creation of de novo ETS binding sites in TERT promoter causes increased levels of TERT mRNA and elevated telomerase activity in many cancer types. 25 The current literature shows that TERT promoter mutations have a dominant frequency in glioblastoma (83%), melanoma (71%) and bladder cancer (66%). 26 Moreover, an heterogeneous distribution of such mutations has been reported in SCC from different anatomical sites including skin SCC (74%), urothelial carcinoma (70%) and head and neck SCC (16.7%). 27 The study of 326 different cell lines derived from several cancer types by whole-genome DNA and deep RNA sequencing analyses showed that the frequency of activating TERT promoter mutations in cell lines is similar to that of the respective primary tumour types. 28 Importantly, near half of the tested cell lineages showed monoallelic telomerase expression and all TERT promoter mutated cell lines showed telomerase transcription exclusively from the mutated allele implying an important role of cis-acting non-coding mutations in cancer. 28 In their study, no cervical cancer cell lines have been analyzed for TERT promoter mutations and allelic expression.
The aim of the present study was to further evaluate the prevalence of TERT promoter mutations in specific histological groups of HPV-related tumours such as cervical SCC and AC as well as oral and oropharyngeal SCC. Four HPVpositive cervical cancer derived cell lines, namely C-4I, CaSki, HeLa and SiHa, have been also included in the analyses. Moreover, we analyzed the functional consequence of TERT promoter mutations in HPV-positive SCC and in cervical cancer cell lines, in which the E6 oncoprotein is known to transactivate TERT expression. Additionally, we have also included in the analysis cervical lesions at different neoplastic stages (CIN 1-3) to investigate whether such mutations act as "trunk" alterations arising at early stages of cervical cancer. Our findings highlight the importance of TERT promoter mutations as key events in specific histotypes of cervical SCC and head and neck SCC.
Materials and Methods

Patient samples and cell lines
Fresh frozen biopsies of head and neck SCC (n 5 9) and cervical SCC (n 5 28) as well as paired non-tumour tissues were obtained from patients referred to the Head and Neck Surgery and Gynaecology Units, respectively, at the Istituto Nazionale Tumori IRCCS "Fond Pascale". Each biopsy was divided in two sections: the first was stored in RNA Later (Ambion, Austin, TX) at 2808C, the second was sent to the pathology laboratory for histopathologic assessment. Similarly, paired non-tumour biopsies were divided in two sections and subjected to molecular analyses and histopathologic examination. Archived formalin fixed paraffin embedded (FFPE) head and neck SCC (n 5 15), cervical carcinoma (n 5 97) and CIN (n 5 62) biopsies were also analyzed. Specifically, from each paraffin block one initial 5-mm thick section, four consecutive 10 mm sections and a final 5-mm thick section were cut from the same block. The initial and final sections were stained with haematoxylin-eosin and assessed by the pathologists for the presence of neoplastic tissue, while the four inner 10 mm sections were collected in micro-tubes for DNA extraction. The neoplastic cell content of FFPE biopsies ranged from 60 to 90% for tumour cases and from 20 to 70% for CIN cases.
The human cervical tumour cell lines C-4I (ATCC CRL-1594), CaSki (ATCC CRL-1550), HeLa (ATCC CCL-2) and SiHa (ATCC HTB-35) were cultivated in Dulbecco's modified Eagle's medium containing 4.5 g/L glucose, 10% foetal bovine What's new? Which cancer types carry mutations in the TERT promoter? HPV16, a frequent cause of oropharyngeal SCC and cervical SCC, can activate the TERT (telomerase reverse transcriptase) promoter. Here, the authors looked for TERT promoter mutations in various types of HPV-related cancers. They found that 60% of oral SCC and 22% of cervical SCC had mutations that activated the TERT promoter, but such changes were rare in oropharyngeal cancer and cervical adenocarcinoma. Furthermore, they noted that the frequency of the mutations was independent of HPV infection status.
serum, 100 U/mL penicillin-streptomycin and cultured under standard conditions (pH 7.4, 378C, 5% CO 2 ). The study is in accordance with the principles of the Declaration of Helsinki and was approved by the Institutional Scientific Board and the Ethical Committee of the Istituto Nazionale Tumori "Fondazione Pascale".
DNA and RNA extraction
Genomic DNA was extracted from approximately 10 mg of fresh frozen tissues and 5 3 10 6 cultured cells by digestion with proteinase K (150 lg per mL at 378C for 10 hr) in 100 lL of lysis buffer (10 mM Tris-HCl pH 7.6, 5 mM EDTA, 150 mM NaCl, 1% SDS), followed by extraction with phenol-chloroform-isoamyl alcohol (25:24:1) and ethanol precipitation in 0.3 M sodium acetate (pH 4.6). 29 DNA was extracted from paraffin embedded tissues as described previously. 30 Total RNA was extracted from all fresh frozen samples and cultured cells using RNeasy MiniKit (Qiagen, Hilden, Germany). The quality and quantity of isolated nucleic acids was spectrophotometrically assessed with Nanodrop 2000C (Thermo Fisher Scientific, Waltham, MA). All samples with a ratio of absorbance at 260 and 280 nm equal or above 1.8 were included for further analyses.
TERT promoter mutational analysis TERT promoter region was amplified using the oligoprimers hTERT-F (5 0 -ACGAACGTGGCCAGCGGCAG-3 0 ) and hTERT-R (5 0 -CTGGCGTCCCTGCACCCTGG-3 0 ), which generate a 474 bp fragment covering the rs2853669 A to G single nucleotide polymorphism and hot spot mutations at nucleotides 2124 and 2146 before TERT ATG start site. PCR negative samples were further amplified with oligonucleotides hTERT_short_F (5 0 -CAGCGCTGCCTGAAACTC-3 0 ) and hTERT_short_R (5 0 -GTCCTGCCCCTTCACCTT-3 0 ) which generate fragments of 163 bp encompassing the hot spot TERT promoter region. PCR reactions were performed in 50 mL reaction mixture containing 30-300 ng of genomic DNA, 10 pmol of each primer, 1.25 Unit of Hot Master Taq DNA Polymerase (5 Prime GmbH, Hamburg, Germany) and 25 mL of PreMix J (Master Amp PCR, Epicentre, Madison, WI). DNA was amplified in Sure Cycler 8800 thermal cycler (Agilent Technologies, Santa Clara, CA) starting with an initial denaturation at 948C for 3 min, followed by 45 amplification cycles of denaturation at 948C for 30 sec, annealing at 658C for 30 s, elongation at 728C for 1 min and 10 min final elongation at 728C. All samples were subjected to automated bi-directional direct sequencing analysis (Eurofins Genomics GmbH, Ebersberg, Germany). All mutations were confirmed by repeating the PCR reactions and the bi-directional sequencing.
HPV detection by PCR and nucleotide sequencing HPV detection was carried out by nested PCR amplifying 30-300 ng of genomic DNA with MY09/MY11 primer pairs for the outer reaction and MGP primer system for the inner reaction in 50 lL reaction mixture containing 5 lL of outer reaction. 30 The method has been previously validated as proficient for the detection of twelve high risk HPV genotypes being able to detect 50 genome equivalents (GE) of HPV 16 and HPV 18 DNA in 5 lL sample with a specificity above 97% through a reference-test proficiency panel as part of the 2010 WHO LabNet study for validating HPV genotyping tests. 31 HPV genotypes were identified by direct automated DNA sequencing analysis of MGP amplified products using the primer GP51 (Eurofins Genomics GmbH, Ebersberg, Germany). 32 The HPV genotypes were identified by the alignment of unknown HPV nucleotide sequences with those present in the GenBank database using the BLASTn software (http://www.ncbi.nlm.nih.gov/blast/html).
TERT and HPV E6/E7 expression by RT PCR
For each sample 500 ng of total RNA were reverse transcribed in 20 lL volume containing 4 lL of iScript reaction mix, 1 lL of iScript reverse transcriptase (Bio-Rad Laboratories Inc., Hercules, CA) and nuclease-free water. The reactions were incubated at 258C for 5 min, at 428C for 30 min and at 858C for 5 min in the Gene Amp PCR System 2400 (Applied Biosystems, Foster City, CA). TERT expression levels were evaluated by real-time PCR using forward (5 0 -CGGAAGAGTGTCTGGAGCAA-3 0 ) and reverse (5 0 -GG-ATGAAGCGGAGTCTGGA-3 0 ) primers targeting TERT exon 3 and exon 4, respectively, which encompassing the intron 3 allow to exclude cross contamination of cDNA with genomic DNA. The samples have been analyzed previously for HPV16 early (E2/E4, E5, E6, E6*I, E6*II, E7) and late (L1 and L2) transcripts by real-time PCR. 29 The reaction mixtures included 12.5 lL of 13 iQ SYBR Green supermix (Bio-Rad Laboratories Inc., Hercules, CA), 10 pmol of each primer, 1 lL of cDNA and nuclease-free water in a final volume of 25 lL. All amplifications were performed in duplicate using the CFX96 Real-Time PCR Detection System (Bio-Rad Laboratories Inc., Hercules, CA). The expression of each gene was analyzed with the 2 -DCt method using GAPDH as a reference. The DCt values for each amplified transcript were calculated by subtracting the respective Ct value from the corresponding GAPDH Ct (DCt 5 Ct x -Ct GAPDH ). The Ct values were corrected for primer pairs efficiency to compare the expression levels of different genes. Standard curves were derived from serial dilutions of SiHa cDNA to calculate the efficiency of each primer set.
Statistical analysis
Statistical analysis was performed with GraphPad version 6 (Prism). Unpaired t-test was used for comparisons of continuous variables; Yates-corrected v 2 test and, where appropriate, two-sided Fisher's exact test were used for comparison of categorical data. Mann-Whitney U-test was used to evaluate differences in gene expression levels between samples. All variables with p < 0.05 were considered statistically significant.
Results
We analyzed tumour biopsies from 24 head and neck cancer and 125 cervical cancer patients as well as CIN biopsies from 62 women previous diagnosed with abnormal cytology. The majority of cancer cases (n 5 112) and CIN lesions (n 5 62) were FFPE biopsies earlier characterized for HPV status and viral genotypes. 29, 33 In addition, 37 cancer cases were available as fresh frozen biopsies along with autologous peritumour tissues. Epidemiological, clinical and pathologic data of cancer cases are described in Table 1 . Human cervical cancer cell lines C-4I, CaSki, HeLa and SiHa were also included in our study.
TERT promoter mutations and HPV in head and neck cancer HPV sequences were searched in all head and neck cancers and viral sequences of genotype 16 were identified in two out of 11 oral tongue SCC (18.2%) and in five out of nine (55.6%) oropharyngeal SCC (Table 1) . Mutations in the TERT promoter region were remarkably frequent in oral SCC (60%) but absent in oropharyngeal SCC (p 5 0.007, Fisher exact test), Table 2 . The hot spot nucleotide changes G to A at position 2124 and 2146 accounted for 33.3 and 22.2%, respectively, of all mutations in oral SCC. Additionally, nucleotide transitions (G to A) at nucleotide 2113, 2126, and 2144 creating putative binding sites for ETS factor family members and (G to T) at nucleotide 2117 creating a NFKB1 putative binding site, were identified in oral cancer cases ( Table 2 ). The mutation frequency of TERT promoter in oral tongue SCC was remarkably high (63.6%). Interestingly, seven out of nine (77.8%) oral cancers with TERT promoter mutations were in the oral tongue. Both HPV16-positive oral SCC harboured TERT promoter mutations (Table 3) .
TERT promoter mutations and HPV in cervical cancer
Overall HPV DNA sequences were detected in 94 out of 125 cervical cancer cases (75.2%). However, there was a significant difference in the HPV detection rate between fresh frozen cervical SCC biopsies (92.8% HPV positive) and FFPE cervical SCC (68.5% HPV positive) or FFPE cervical AC (75% HPV positive). The difference was likely due to the fragmentation of DNA from FFPE tissues and the use of broad spectrum MY09/ MY11 primer pair targeting a relatively large fragment.
The overall frequency of TERT promoter mutations in cervical cancer was 18.4% (23 out of 125 samples), (Tables 2 and 3 ). The hot spot nucleotide changes G to A at positions 2124 and 2146 accounted for 43.5 and 30.4% of all mutations, respectively, while other mutations represented 26.1% of all nucleotide changes. The G to A transition at position 2146 was also identified in SiHa cell line DNA but not in HeLa, CaSki and C-4I. Other nucleotide variations were detected at positions 2106; 2111; 2112; 2115 and 2151 upstream the TERT ATG start site and always implicated a G to A transversion with the exception of one G to T transition at position 2106 (Fig. 1) . These mutations lead to changes in transcription factor-binding sites including creation of putative ETS, KLF5 and THAP1 binding motifs (Table 2) . Interestingly, TERT promoter mutations have a dominant frequency in cervical SCC histotype (21.8%, 22 out of 101) and a limited occurrence in cervical AC (4.2%).
The nucleotide sequencing analysis of HPV and TERT promoter amplimers in tumour and peri-tumour DNA available for 20 patients showed the same HPV genotype in the paired samples but none of the peri-tumour tissues carried mutations in the TERT promoter region. TERT promoter hot spot mutations were all heterozygous, except for the nucleotide change at position 2151 in the TERT promoter which being hemizygous indicates the loss of the second allele (Fig. 1) . No TERT promoter mutations were identified in cervical AC samples except for a G to A change at position 2112 upstream TERT ATG start site.
Sixty-two cases of histological confirmed CIN were analyzed for nucleotide changes in the promoter region of TERT gene. Twenty-three biopsies were diagnosed as CIN3, 29 as CIN2 and 10 as CIN1. A nucleotide change at position 2105 upstream TERT ATG start site was identified in a single CIN3 case (4.3%) and no other TERT promoter mutations were detected in CIN lesions (Table 2) .
TERT expression levels
Total RNA was available from six oropharyngeal SCC along with seven paired peri-tumour tissues, 16 cervical SCC and 5 CIN to study TERT gene expression levels by quantitative real-time PCR. All these samples have been previously analyzed in terms of HPV genotypes and HPV16 gene expression profiles. 29 The E6 mRNA levels in virus positive oropharyngeal SCC were previously found to be very low in oropharyngeal biopsies thus the E6 activity on TERT promoter might be limited in this tumour type. The oropharyngeal SCC, lacking mutations in TERT promoter, showed TERT mRNA levels comparable to those detected in peri-tumour tissues (Fig. 2) . However, significant higher levels of TERT transcripts were observed in TERT promoter mutated cervical SCC (n 5 6) compared to not mutated tumours (n 5 10), (p 5 0.04, t-test) and to CIN lesions (n 5 5), (p 5 0.004), Figure 2 . A 1 Position refers to distance from the ATG start site. 2 Number of tumours with TERT promoter mutations. 3 Putative transcription factors binding sites identified by JASPAR database (http://jaspar.genereg.net). 4 Cell lines include HeLa, SiHa, CaSki, and C4I. statistical significant difference in TERT transcript levels was also observed between not mutated cervical SCC and CIN lesions (p 5 0.03). The HPV16 E6 and E7 RNA levels were also evaluated in all cervical samples and no correlation was found between E6 oncogene expression and TERT mRNA levels.
TERT promoter mutations and expression levels in cervical cancer cell lines
The nucleotide sequencing analysis of TERT promoter in cervical carcinoma cell lines containing HPV16 (CaSki and SiHa) or HPV18 (HeLa and C-4I) showed the presence of G to A transition at position 2146 in the HPV16-positive SiHa DNA. Quantitative RT-PCR of TERT mRNA from the four cervical cancer cell lines showed TERT mRNA levels 10-fold and 6-fold higher in the mutated SiHa cells compared to CaSki and HeLa cells, respectively, and 2-fold higher expression than C-4I cells (Fig. 3b) . There was no correlation between HPV16 E6 mRNA levels and TERT expression. Interestingly HeLa and C-4I cell lines expressing highest levels of E6 showed lower level of TERT mRNA compared to SiHa and CaSki cell lines (Fig. 3a) .
Discussion
The main risk factors for head and neck SCC are tobacco use and alcohol consumption which alone or in combination exert a cytotoxic and mutagenic effect on the mucosal epithelia of upper aerodigestive tract. [34] [35] [36] The most common molecular alterations in head and neck SCCs are somatic nucleotide changes in the exonic regions of TP53, NOTCH1 and IRF6 genes as well as homozygous deletion and mutations in CDKN2A and CCND1 genes. [37] [38] [39] The frequency of mutations has shown to be significantly higher in HPVnegative compared to HPV-positive tumours, although some genes, including NOTCH1, HRAS and PIK3CA, have similar mutation rates in the two cancer groups. 38, 39 The importance of mutations in non-coding regions of human genomes, such as those affecting enhancers, promoters, insulators and other regulatory regions, have been known for a long time but their relevance in cancer development has not been comprehensively studied. 40 The recent discovery of two activating mutations within the core promoter of the TERT gene prompted the significant role of such genetic event in the development of many cancer types. 22 In the current study, we investigated the presence of TERT promoter mutations in head and neck cancers and confirmed the high rate of hot spot nucleotide changes in oral SCC (60%), particularly in tongue tumours, and the rarity of such mutations in oropharyngeal SCC. 22, 41, 42 The expression level of telomerase was comparable in HPV-positive and HPV-negative oropharyngeal SCC suggesting that the low expression of E6 and E7 oncoproteins, previously shown in these tumours, has little effect on the activation of TERT promoter. 29 In addition to the hot spot changes a significant number of other mutations consisting in G to A or in G > T transitions have been detected in oral SCC (26.7%). Some not recurrent mutations were hemizygous suggesting the loss of the chromosomal region 5p. These types of mutations can be attributed to APOBEC cytidine deaminase expression during cancer development and to the exposure of oral epithelium to carcinogens. 43 In most cases these changes created putative ETS binding sites and probably concurred to TERT activation.
The main oncogenic players in cervical carcinoma are the E6 and E7 proteins of high risk HPVs. However, recent studies performed on the exonic sequences of human genome showed that APOBEC mutagenesis patterns and mutations in HKBP1, ERBB3, CASP8, HLA-A and TGFBR2 genes, together with the already known nucleotide variations in PIK3CA, EP300, FBXW7, HLA-B, PTEN, NFE2L2, ARID1A, KRAS and MAPK1 genes, represent important genetic events in cervical cancer. 44 Most of the mutated genes are common to SCC and AC tumours, however, some of them including LA-A, HLA-B, NFE2L2, MAPK1, CASP8, SHKBP1 and TGFBR2 have been found exclusively in squamous tumours and several others including TP53 differently distributed between the two types of tumours. 44, 45 In the present study, we analyzed the TERT promoter region in cervical carcinoma and CIN lesions from Italian women and we observed TERT promoter mutations in 21.8% (22/101) of cervical SCC, in 4.2% (1/24) of AC and in 1.6% (1/62) of CIN lesions. These results are in agreement with that reported by Vinothkumar et al. 41 describing TERT promoter mutation rate of 21.4% (30/140) among Indian cervical SCC. Conversely, other studies reported a very low frequency (0-5%) of such mutations in cervical SCC. 22, 27, 46 These differences are probably due to the small number of samples analyzed in the early studies or to the different ethnicity of the enrolled patients. Moreover, the rarity of hot spot TERT promoter mutations in CIN lesions suggests that this is a late event in cervical neoplasia development.
The telomerase activity is regulated by reversible mechanisms such as TERT gene transcription regulation, TERT premRNA alternate splicing and post-translational modifications, as well as by irreversible mechanisms such as genetic alterations and TERT promoter mutations. The E6 and E7 oncoproteins of high risk HPVs, but not those of low risk viruses, are able to transactivate TERT promoter. 48 Indeed, the positivity for HPV E6/E7 mRNA has been found to correlate with TERT mRNA expression in cervical lesions of different histological grades (CIN1 to CIN3) and in cervical SCC. 47 In accordance, we observed higher expression of TERT mRNA in cervical SCC compared to CIN (p 5 0.03). Moreover, telomerase levels were statistically significantly higher in TERT promoter mutated cervical SCC compared to not mutated SCC cases (p 5 0.04) in the presence of comparable levels of HPV16 E6 and E7 mRNAs suggesting that the mutations have a much stronger effect in TERT promoter activation than viral oncoproteins.
Cell lines, derived from tumour types with high frequency of TERT promoter mutations, frequently harbour such mutations. 28 Huang et al. by performing whole genome and RNA sequencing of a large panel of cell lines from different tumour types identified 60 mutated lineages (18.23%) and all of them showed TERT mRNA monoallelic expression driven by the mutated promoter. 28 We have analyzed cervical carcinoma derived cell lines SiHa, CaSki, HeLa and C-4I and we found the hot spot nucleotide change 2146G to A only in SiHa cells derived from a cervical SCC. 49 The expression levels of telomerase mRNA was much higher in SiHa cells compared to the other cell lines, while the expression levels of HPV E6 were comparable, suggesting, once again, that the mutation has a major effect on the TERT activation.
In conclusion, we found that TERT promoter mutations were most common in oral carcinoma, especially when the tumours arose in the oral tongue, and very common in cervical SCC. TERT promoter mutations were associated with higher TERT mRNA levels in cervical carcinoma biopsies and SiHa cell line. These results suggest an important role of TERT promoter mutations and increased telomerase expression in the development of a significant fraction of oral and cervical SCC. Further studies are needed to establish whether telomerase inhibitors, such as nucleosides 3-Azido-2,3-dideoxythymidine (azidothymidine [AZT]), Gquadruplex stabilizers, oligonucleotides and small molecules, 50 will become useful for the treatment of cervical and head and neck cancers.
